Ascend Wellness (AAWH) investor relations material

Executive summary

• Q3 2025 net revenue was $124.7 million, down 2% sequentially, with retail sales at $83.8 million and wholesale at $41 million.

• Adjusted EBITDA rose 8.9% quarter-over-quarter to $31.1 million, with margin expanding to 24.9%.

• Net loss for the quarter was $25.8 million, compared to $24.4 million in Q2 2025.

• Strategic focus remains on profitability, sustainability, and market densification, with over $30 million in annual expenses eliminated.

• Seven new stores were added year-to-date, expanding the footprint to 46 locations, with a pipeline targeting 60 within 12 months.

Financial highlights

• Adjusted gross profit for Q3 was $57.8 million, up 4.6% sequentially; adjusted gross margin improved by 300 bps to 46.4%.

• Operating cash flow was slightly negative due to a $19.1 million biannual interest payment; cash ended at $87.3 million.

• SG&A expenses remained flat; margin expansion was driven by improved vertical sales mix and purchasing efficiencies.

• $6.4 million in CapEx and $5.5 million in M&A payments during the quarter; full-year CapEx expected at $30–$35 million.

• Net Debt at quarter-end was $281.8 million.

Outlook and guidance

• Q4 revenue expected to be slightly down due to holiday promotions and ongoing industry headwinds.

• Adjusted EBITDA margin projected to exceed 23% in Q4, with stronger cash flow anticipated due to interest payment timing.

• Densification strategy aims to reach 60 total locations within 12 months, with 13 stores in the pipeline.

• Continued focus on cost control, operational efficiency, and margin improvement.

• Ongoing investments in product innovation and customer engagement platforms to drive long-term loyalty and margin expansion.